Skip to main content
. 2015 Aug 27;11(10):1891–1904. doi: 10.1080/15548627.2015.1085742

Figure 8.

Figure 8.

Primary tumor cells derived from a patient who progressed on sunitinib, were sensitive to sunitinib when in the presence of elacridar or elacridar and LLOM. Determination of the percentage of viable/dead TFE3 cells after incubation for 24 h with the indicated combinations of drugs (sunitinib (sun) 2.5 μmol/L; LLOM (L) 0.2 μmol/L; elacridar (E) 1 μmol/L). *, P < 0.05; ***, P < 0.001.